MDxHealth SA $MDXH Shares Bought by Delta Investment Management LLC

Key Points

• Delta Investment Management LLC significantly increased its stake in MDxHealth SA, owning 190,100 shares after a 459.1% increase in the first quarter, totaling approximately $270,000.
• MDxHealth has received a "buy" rating from Craig Hallum with a price target of $8.00, and currently holds a consensus rating of "Buy" with an average price target of $7.00.
• The company reported negative earnings per share of ($0.15) last quarter, missing expectations, amid a market capitalization of $169.77 million.

Delta Investment Management LLC lifted its stake in MDxHealth SA (NASDAQ:MDXH - Free Report) by 459.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 190,100 shares of the company's stock after purchasing an additional 156,100 shares during the period. Delta Investment Management LLC owned about 0.40% of MDxHealth worth $270,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC purchased a new stake in MDxHealth in the fourth quarter worth about $25,000. Castleview Partners LLC purchased a new stake in MDxHealth in the first quarter worth about $48,000. FAS Wealth Partners Inc. lifted its stake in MDxHealth by 49.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock worth $58,000 after acquiring an additional 8,100 shares during the period. XTX Topco Ltd purchased a new stake in MDxHealth in the fourth quarter worth about $63,000. Finally, Renaissance Technologies LLC lifted its stake in MDxHealth by 715.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock worth $292,000 after acquiring an additional 108,000 shares during the period.

MDxHealth Stock Performance

NASDAQ:MDXH traded up $0.03 during midday trading on Tuesday, hitting $3.58. The company's stock had a trading volume of 41,966 shares, compared to its average volume of 91,779. MDxHealth SA has a fifty-two week low of $1.35 and a fifty-two week high of $3.81. The firm's 50 day moving average is $2.61 and its 200-day moving average is $2.06. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.31 and a quick ratio of 1.22. The firm has a market cap of $169.06 million, a P/E ratio of -4.06 and a beta of 1.48.

MDxHealth (NASDAQ:MDXH - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The firm had revenue of $26.60 million for the quarter, compared to analyst estimates of $26.60 million. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. Equities analysts anticipate that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MDXH has been the subject of several analyst reports. Wall Street Zen raised shares of MDxHealth to a "hold" rating in a research report on Saturday. Craig Hallum initiated coverage on shares of MDxHealth in a research report on Thursday, July 17th. They set a "buy" rating and a $8.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, MDxHealth has an average rating of "Buy" and a consensus target price of $7.00.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.